Teleflex Incorporated (NYSE:TFX) Shares Sold by Brown Brothers Harriman & Co.

Brown Brothers Harriman & Co. lowered its position in shares of Teleflex Incorporated (NYSE:TFX) by 2.5% in the second quarter, Holdings Channel reports. The institutional investor owned 2,555 shares of the medical technology company’s stock after selling 65 shares during the period. Brown Brothers Harriman & Co.’s holdings in Teleflex were worth $1,027,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently made changes to their positions in TFX. Price T Rowe Associates Inc. MD increased its holdings in shares of Teleflex by 0.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,970,209 shares of the medical technology company’s stock valued at $2,064,923,000 after purchasing an additional 31,317 shares in the last quarter. Janus Henderson Group PLC boosted its stake in shares of Teleflex by 9.8% during the 1st quarter. Janus Henderson Group PLC now owns 997,221 shares of the medical technology company’s stock worth $414,307,000 after purchasing an additional 89,000 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Teleflex by 3.4% during the 2nd quarter. Geode Capital Management LLC now owns 793,718 shares of the medical technology company’s stock worth $317,984,000 after purchasing an additional 25,954 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Teleflex by 5.5% during the 1st quarter. Bank of New York Mellon Corp now owns 679,120 shares of the medical technology company’s stock worth $282,148,000 after purchasing an additional 35,505 shares during the last quarter. Finally, Franklin Resources Inc. boosted its stake in shares of Teleflex by 1.1% during the 2nd quarter. Franklin Resources Inc. now owns 629,646 shares of the medical technology company’s stock worth $252,987,000 after purchasing an additional 6,668 shares during the last quarter. Institutional investors own 91.38% of the company’s stock.

TFX opened at $354.51 on Thursday. The firm has a market capitalization of $16.59 billion, a P/E ratio of 47.84, a P/E/G ratio of 1.91 and a beta of 1.19. The firm’s 50 day moving average is $380.45 and its 200-day moving average is $398.08. Teleflex Incorporated has a 52-week low of $312.33 and a 52-week high of $449.38. The company has a quick ratio of 1.80, a current ratio of 2.73 and a debt-to-equity ratio of 0.64.

Teleflex (NYSE:TFX) last posted its quarterly earnings data on Thursday, July 29th. The medical technology company reported $3.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.87 by $0.48. The company had revenue of $713.47 million for the quarter, compared to analyst estimates of $680.85 million. Teleflex had a net margin of 13.06% and a return on equity of 17.29%. During the same quarter last year, the firm posted $1.93 earnings per share. Equities analysts expect that Teleflex Incorporated will post 12.97 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 15th. Stockholders of record on Monday, August 16th were paid a dividend of $0.34 per share. The ex-dividend date of this dividend was Friday, August 13th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.38%. Teleflex’s dividend payout ratio is currently 12.75%.

TFX has been the topic of several research analyst reports. SVB Leerink raised their target price on shares of Teleflex from $410.00 to $415.00 and gave the stock a “market perform” rating in a research report on Friday, July 30th. Needham & Company LLC initiated coverage on shares of Teleflex in a research report on Friday, July 9th. They issued a “buy” rating and a $486.00 target price on the stock. Jefferies Financial Group initiated coverage on shares of Teleflex in a research report on Friday, September 10th. They issued a “buy” rating and a $485.00 target price on the stock. KeyCorp decreased their target price on shares of Teleflex from $448.00 to $439.00 and set an “overweight” rating on the stock in a research report on Monday, August 2nd. Finally, JMP Securities restated a “market outperform” rating on shares of Teleflex in a report on Friday, July 30th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $455.80.

In other news, CEO Liam Kelly sold 8,987 shares of Teleflex stock in a transaction that occurred on Wednesday, August 18th. The shares were sold at an average price of $376.32, for a total transaction of $3,381,987.84. Following the sale, the chief executive officer now owns 34,762 shares in the company, valued at $13,081,635.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 1.34% of the company’s stock.

About Teleflex

Teleflex, Inc provides medical technology products which enables healthcare providers to improve patient outcomes and enhance patient and provider safety. The firm designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications.

Further Reading: What is the Gross Domestic Product (GDP)?

Want to see what other hedge funds are holding TFX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teleflex Incorporated (NYSE:TFX).

Institutional Ownership by Quarter for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.